DoubleRainbow Biosciences

DoubleRainbow Biosciences, founded in 2016 and based in San Diego, is a private biotechnology company leveraging synthetic biology to address supply chain and sustainability challenges in natural product manufacturing. The company's core technology, the PRISM enzyme modification platform, is designed to glycosylate medicinal compounds to improve their solubility, potency, and efficacy. DoubleRainbow aims to create sustainable therapeutics, nutraceuticals, and agricultural solutions, positioning itself at the intersection of human health and environmental stewardship. It operates as a platform company and is currently in a pre-revenue, pre-clinical stage of development.

PRISM (Enzyme Modification Platform): A proprietary platform that uses a library of enzymes to glycosylate natural or synthetic medicinal compounds with specific sugar motifs to improve their solubility, potency, and efficacy.

DoubleRainbow competes in the broad synthetic biology sector with companies like Ginkgo Bioworks and Amyris, which also engineer microbes to produce compounds. Its specific focus on glycosylation for drug improvement differentiates it, but it faces competition from both platform companies and pharmaceutical firms investing in internal biocatalysis and sustainable sourcing initiatives.